ScholarIQanswers from OpenAlex & ORCID
Fabrice Barlési
ResearcherPublications, citations & collaboration network
Fabrice Barlési is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Fabrice Barlési have?
ScholarIQindexed works
Fabrice Barlési has 1,476 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Fabrice Barlési have?
ScholarIQcitation count
Fabrice Barlési has 73,321 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Fabrice Barlési?
ScholarIQh-index
Fabrice Barlési has an h-index of 100 in OpenAlex.
What is the i10-index of Fabrice Barlési?
ScholarIQi10-index
Fabrice Barlési has an i10-index of 427 in OpenAlex.
What is the ORCID of Fabrice Barlési?
ScholarIQorcid
The ORCID for Fabrice Barlési is on the source record.
What is the OpenAlex record for Fabrice Barlési?
ScholarIQopenalex
The OpenAlex for Fabrice Barlési is on the source record.
What are the most-cited papers on Fabrice Barlési?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn, David R. Spigel, Martin Steins, Neal Ready, Laura Q.M. Chow, Everett E. Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlési, Martin Kohlhäufl, Óscar Arrieta, M. Burgio, Jérôme Fayette, H. Lena, Elena Poddubskaya, David E. Gerber, Scott Gettinger, Charles M. Rudin, Naiyer A. Rizvi, Lucio Crinò, George R. Blumenschein, Scott Antonia, Cécile Dorange, Christopher Harbison, F. Graf Finckenstein, Julie R. Brahmer
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Francesco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez‐Abreu, Denis Moro‐Sibilot, Christian A. Thomas, Fabrice Barlési, Gene Grant Finley, Claudia Kelsch, Anthony Lee, Shelley Coleman, Yu Deng, Yijing Shen, Marcin Kowanetz, Ariel López-Chávez, Alan Sandler, Martin Reck
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro, Bogdan Żurawski, Sang‐We Kim, Enric Carcereny, Keunchil Park, Aurelia Alexandru, Lorena Lupinacci, Emmanuel de la Mora Jimenez, Hiroshi Sakai, István Albert, A. Vergnenègre, Solange Peters, Konstantinos Syrigos, Fabrice Barlési, Martin Reck, Hossein Borghaei, Julie R. Brahmer, Kenneth J. O’Byrne, William J. Geese, Prabhu Bhagavatheeswaran, Sridhar K. Rabindran, Ravi S. Kasinathan, Faith E. Nathan, Suresh S. Ramalingam
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Silvia Novello, Fabrice Barlési, Raffaele Califano, Tanja Čufer, Simon Ekman, Matteo Giaj Levra, Keith M. Kerr, Sanjay Popat, Martin Reck, Suresh Senan, G.V. Simo, Johan Vansteenkiste, Solange Peters